• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Quince Therapeutics Inc.

    6/11/26 12:02:10 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $QNCX alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox not checkedNoneEntity Type
    0001662774
    Cortexyme, Inc.
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Quince Therapeutics, Inc.
    Jurisdiction of Incorporation/Organization
    CALIFORNIA 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Quince Therapeutics, Inc.
    Street Address 1Street Address 2
     611 Gateway Blvd., Suite 273
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     South San Francisco
     CALIFORNIA
     
     94080
     415-910-5717 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Thye
    Dirk
    Street Address 1Street Address 2
     611 Gateway Blvd., Suite 273 
     
    CityState/Province/CountryZIP/Postal Code
     South San Francisco
     CALIFORNIA
     94080
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Roberts
    Brigette
    Street Address 1Street Address 2
     611 Gateway Blvd., Suite 273 
     
    CityState/Province/CountryZIP/Postal Code
     South San Francisco
     CALIFORNIA
     94080
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Ryan
    Charles
    Street Address 1Street Address 2
     611 Gateway Blvd., Suite 273 
     
    CityState/Province/CountryZIP/Postal Code
     South San Francisco
     CALIFORNIA
     94080
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Hannah
    Brendan
    Street Address 1Street Address 2
     611 Gateway Blvd., Suite 273 
     
    CityState/Province/CountryZIP/Postal Code
     South San Francisco
     CALIFORNIA
     94080
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Lamond
    David
    Street Address 1Street Address 2
     611 Gateway Blvd., Suite 273 
     
    CityState/Province/CountryZIP/Postal Code
     South San Francisco
     CALIFORNIA
     94080
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Senner
    Christopher
    Street Address 1Street Address 2
     611 Gateway Blvd., Suite 273 
     
    CityState/Province/CountryZIP/Postal Code
     South San Francisco
     CALIFORNIA
     94080
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Bray
    June
    Street Address 1Street Address 2
     611 Gateway Blvd., Suite 273 
     
    CityState/Province/CountryZIP/Postal Code
     South San Francisco
     CALIFORNIA
     94080
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-05-18
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button checked Yes Radio button not checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button checked Yes Radio button not checked No
    Clarification of Response (if Necessary)
    The Issuer issued 2,210,899 shares of common stock, 52,153.299 shares of preferred stock, and warrants to purchase up to 7,410.644 shares of preferred stock in connection with its acquisition of Orphai Technologies, Inc.
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     LifeSci Capital
     000168404
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    1700 Broadway, 40th Floor
     
    City State/Province/CountryZIP/Postal Code
     New York
     NEW YORK
     10019
    State(s) of SolicitationCheckbox checkedAll StatesCheckbox not checkedForeign/Non-US
     




    13. Offering and Sales Amounts
     
    Total Offering Amount $
    7387671
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    0
    USD
    Total Remaining to be Sold $
    7387671
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
    Offering amount includes aggregate gross proceeds that may be received in the future upon the cash exercise in full of the warrants.
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    66
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    1800000
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Quince Therapeutics, Inc./s/ Dirk ThyeDirk ThyeChief Executive Officer2026-06-11




    Get the next $QNCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNCX

    DatePrice TargetRatingAnalyst
    6/24/2026$4.00Outperform
    Leerink Partners
    6/23/2026$4.00Overweight
    Cantor Fitzgerald
    1/30/2026Mkt Outperform → Mkt Perform
    Citizens JMP
    8/5/2025$9.00Mkt Outperform
    Citizens JMP
    3/24/2025$10.00Outperform
    Oppenheimer
    More analyst ratings

    $QNCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    9/3/24 5:38:44 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    8/22/24 5:51:16 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    8/21/24 6:38:07 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

    Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeksPhase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (

    5/18/26 10:21:49 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

    Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS)$115 million in upfront financing with the potential to receive up to an additional $72 million upon exercise of accompanying warrantsUpfront proceeds from the private placement and existing cash and cash equivalents at closing are expected to fund operations through the end of 2028 and to support multiple expected milestones, including initiation of a Phase 2b trial in PH-ILD with data anticipated in Q1 2028 and delivery of Phase 2 data in BOS in Q

    5/18/26 9:26:51 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

    Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH demonstrated clinically meaningful improvement in multiple assessments of lung function, including improvement in 6MWD of 67.4 meters and PVR reduction of 33.9% at 24 weeksPhase 2b trial in PH-ILD to initiate in mid-2026, with topline data anticipated in the first quarter of 2028Conference call and webcast today, May 18, 2026, at 10:00 a.m. ET SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (NASDAQ:QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (

    5/18/26 9:26:19 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Quince Therapeutics with a new price target

    Leerink Partners initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $4.00

    6/24/26 8:43:50 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Quince Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Quince Therapeutics with a rating of Overweight and set a new price target of $4.00

    6/23/26 8:24:51 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quince Therapeutics downgraded by Citizens JMP

    Citizens JMP downgraded Quince Therapeutics from Mkt Outperform to Mkt Perform

    1/30/26 6:43:10 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    SEC Filings

    View All

    SEC Form 8-K filed by Quince Therapeutics Inc.

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    6/11/26 5:06:44 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form D filed by Quince Therapeutics Inc.

    D - Quince Therapeutics, Inc. (0001662774) (Filer)

    6/11/26 12:02:10 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form D filed by Quince Therapeutics Inc.

    D - Quince Therapeutics, Inc. (0001662774) (Filer)

    6/11/26 12:01:11 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lamond David

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    6/15/26 5:57:01 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Senner Christopher J.

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    6/15/26 5:51:59 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Corp. Affairs Officer Roberts Brigette

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    6/11/26 5:30:07 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Leadership Updates

    Live Leadership Updates

    View All

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company's Scientific Advisory Board (SAB). Dr. Abolhassani becomes the ninth member to join Quince's SAB, which is comprised of leading experts in Ataxia-Telangiectasia (A-T), biochemistry, neurology, immunology, genetic, hematology, pharmacology, and clinical practice. Dr. Mauro Magnani,

    7/10/25 4:05:00 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn

    1/23/25 4:05:00 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Financials

    Live finance-specific insights

    View All

    Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

    Acquisition includes LAM-001, an inhaled formulation of rapamycin for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS)$115 million in upfront financing with the potential to receive up to an additional $72 million upon exercise of accompanying warrantsUpfront proceeds from the private placement and existing cash and cash equivalents at closing are expected to fund operations through the end of 2028 and to support multiple expected milestones, including initiation of a Phase 2b trial in PH-ILD with data anticipated in Q1 2028 and delivery of Phase 2 data in BOS in Q

    5/18/26 9:26:51 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.

    4/5/23 4:05:00 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

    SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

    11/14/24 4:00:05 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Quince Therapeutics Inc.

    SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)

    11/13/24 9:17:26 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

    SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

    8/6/24 8:04:44 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care